Answers are grounded in this paper and cite their sources.
Despite significant advancements in chemotherapy, surgery, radiotherapy, and immunotherapy, glioblastoma remains incurable, highlighting the urgent need for new treatment strategies. Published studies with extensive data suggest that nanotechnology has potential for treating glioblastoma and may enhance patients' quality of life by minimizing adverse effects through reduced unwanted exposure of organs to chemotherapeutics. However, reports indicate that nanomedicines may cause severe adverse effects compared to other therapies and might not improve overall survival. This could result from insufficient consideration of the "Cold Microenvironment," a subtype of glioblastomas, tumor heterogeneity, and inherent variations from disease models that do not accurately mimic human pathophysiological conditions, among other factors that hinder optimal drug delivery in preclinical and clinical trials. Furthermore, there may be a lack of clear understanding regarding the precise targeting of glioblastomas by nanomedicines or the inherent physiological variations in pharmacokinetics. Developing a thorough understanding of molecular subtypes of GBM and its heterogeneity is believed to facilitate the rapid and safe advancement of precision medicine, moving beyond a one-size-fits-all approach for precision nanomedicine. This review highlights factors and strategies to overcome delivery challenges across heterogeneous barriers, enabling the customization of precision nanomedicine for enhanced therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Farhan Mazahir (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: